Skip to main content
. 2012 Oct-Dec;2(4):483–491. doi: 10.4103/2045-8932.105037

Figure 1.

Figure 1

Rosiglitazone or neutralizing antibodies to TSP-1 or TGF-β1 attenuated hypoxia-induced HPASMC proliferation. HPASMC exposed to normoxic (21% O2) or hypoxic (1% O2) conditions for 72 hours were treated with neutralizing antibodies to either TSP-1 (nTSP-1, 1 μg/ml) or TGF-β1 (nTGF-b1, 1 μg/ml) 3 hours prior to exposure, or rosiglitazone (Rosi, 10 μM) was administered during the last 24 hours of exposure. After treatment, an MTT assay was performed to measure cellular proliferation (n = 6). *P< 0.05 vs. Control-Normoxia, +P< 0.05 vs. Control-Hypoxia, #P< 0.05 vs. Control-Normoxia.